G

GW Research | Chula Vista, CA

Research site

(Unclaimed)

Location

353 Church Avenue, Chula Vista, California, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Vonoprazan

SPD476

CVC

Lanifibranor

Deudomperidone

HTD1801

CDX-0159

Cenicriviroc

CIN-102

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 19 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (EvolvE)

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Enrolling

Eosinophilic Esophagitis

Biological: barzolvolimab

Drug: Matching Placebo

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 2

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes (CENTRICITY)

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting

Nonalcoholic Steatohepatitis (NASH)

Type 2 Diabetes

Drug: Placebo

Drug: HTD1801